Dr. Miron on Resistance Mechanisms to FGFR Inhibitors in Cholangiocarcinoma
Benjamin Miron, MD, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.
Pan-FGFR Inhibitor Seeks to Overcome Resistance Hurdles in Cholangiocarcinoma and Urothelial Carcinoma
Early sensitivity to FGFR inhibition has improved outcomes for patients across tumor histologies; however, kinase domain mutations limit extended efficacy for select patients including those with intrahepatic cholangiocarcinoma or urothelial cancer.
Dr. Roychowdhury on FGFR Mutations in Intrahepatic Cholangiocarcinoma
Sameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.